NCT05024682

Brief Summary

The relatively complex anatomical structure of the pelvis has been a focus of study in the medical field. The diagnosis of the causes of chronic pelvic pain is usually a complicated process. Pudendal neuralgia is a syndrome that is characterized by pelvic pain, including bowel, bladder regional pain or discomfort, sexual dysfunction, severe burning sensations and needle-like pain, which are aggravated when seated and relieved after standing. pudendal neuralgias are induced by pudendal nerve damage The mechanism of PRF has been studied repeatedly. It has been verified that PRF has definite safe treatment range, but during the PRF treatment, the tissue surrounding the electrode may have some degree of change and so it is difficult to assess any actual damage.7 Based on electric field intensity, PRF can actually produce tissue changes observable as in vitro changes to ultrastructure in early-phase histologic study. These biological changes were converted to biological effect to alleviate neuropathic pain in animal models.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 22, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 27, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

January 3, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 3, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 3, 2023

Completed
Last Updated

August 27, 2021

Status Verified

August 1, 2021

Enrollment Period

1 year

First QC Date

August 22, 2021

Last Update Submit

August 22, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • visual analogue score

    The VAS score was used that has 0-10 points. The 0 point represents the painless state and a score from 1 to 3 points represents mild pain, from 4 to 6 points represents moderate pain and from 7 to 10 points represents severe pain.

    3 months

Study Arms (2)

conventional pulsed radiofrequency

EXPERIMENTAL
Device: conventional pulsed radiofrequency

pulse dosed pulsed radiofrequency

EXPERIMENTAL
Device: pulse dosed pulsed radiofrequency

Interventions

After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 120 seconds pulse mode which consisted of four cycles (8 minutes)

conventional pulsed radiofrequency

After connecting the electrode and the PRF needle, the interventionist determined whether the pudendal nerve innervation produced paresthesia in the sensory stimulation test with a frequency of 50 Hz, pulse width of 1 ms and a voltage of 0.3-0.5 V. Thereafter, the radiofrequency ablation therapy was performed in 42°C, 240 seconds pulse dose mode which consisted of two cycles (8 minutes).

pulse dosed pulsed radiofrequency

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • pain located in the pudendal nerve distribution area
  • pain intensity increases in the sitting position;
  • no nocturnal pain symptoms;
  • pain with no objective sensory impairment
  • pain is relieved by diagnostic pudendal
  • the pain symptom is associated with sexual dysfunction, with the elimination of obstetrical and gynaecologic, urological and anorectal diseases in the related departments and absence of any physical and mental disorders;
  • treatment by other departments is invalid;
  • patients should be older than 18 years
  • patients should be able to sign an informed consent form

You may not qualify if:

  • patients have simple tailbone, gluteus muscle or lower abdominal pain, or only paroxysmal pain, or only pruritic symptoms, and/or have imaging anomalies that may explain the symptoms;
  • female patients who are pregnant;
  • patients who take anticoagulant drugs or have any coagulation disorder;
  • patients who are unable to complete the questionnaire;
  • patients with pain, which is caused by malignant or autoimmune diseases and
  • patients who are hypersensitive to metals.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Saeid Metwaly Elsawy

Asyut, 71111, Egypt

Location

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
DR

Study Record Dates

First Submitted

August 22, 2021

First Posted

August 27, 2021

Study Start

January 3, 2022

Primary Completion

January 3, 2023

Study Completion

February 3, 2023

Last Updated

August 27, 2021

Record last verified: 2021-08

Locations